Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000699581 | SCV000828299 | pathogenic | Developmental and epileptic encephalopathy, 26 | 2018-05-02 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with glutamic acid at codon 381 of the KCNB1 protein (p.Gly381Glu). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and glutamic acid. This variant is not present in population databases (ExAC no frequency). This variant has been observed to be de novo in individuals with clinical features of epileptic encephalopathy (Invitae). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. The p.Gly381 amino acid residue in KCNB1 has been determined to be clinically significant (PMID: 26648591). This suggests that variants that disrupt this residue are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic. |
Institute of Human Genetics, |
RCV000699581 | SCV003804666 | uncertain significance | Developmental and epileptic encephalopathy, 26 | 2022-12-23 | criteria provided, single submitter | clinical testing | _x000D_ Criteria applied: PS4_SUP, PM2_SUP, PP2 |